



Product Specification Sheet

Product Name: ABBV-744

Catalog Number: C2874

Technical information:

Chemical Formula: C₂₈H₃₀FN₃O₄

CAS #: 2138861-99-9

Molecular Weight: 491.55

Purity: > 98%


Appearance: Grey solid

Solubility: Soluble in DMSO up to 200 mM

Chemical Name: N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide

Storage: For longer shelf life, store solid powder or DMSO solution at -20°C desiccated.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.



- Handling:**
- To make 10 mM stock solution, add 0.203mL of DMSO for each mg of ABBV-744.
 - For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

Biological Activity: ABBV-744 is a selective bromodomain and extra-terminal (BET) inhibitor that preferentially bind to the 2nd bromodomains (BD) than the 1st BD of BET family proteins (i.e., BRD2, BRD3, BRD4) [1]. This selective targeting of BD2 subsets of the BET bromodomain abolished the broad antiproliferative activities for previous generation pan BET inhibitors, and only display antiproliferative activities in a limited number of cancer cell lines, including acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR) [2]. Improved tolerability is expected due to less impact on global transcription [3].

- Reference:**
1. Sheppard G, et al. Discovery of ABBV-744, a first-in-class highly BDII-selective BET bromodomain inhibitor. *Cancer Res* 2018; 78(Suppl):Abstract nr 931. Pubmed ID: DOI: 10.1158/1538-7445.AM2018-931
 2. Faivre EJ, et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. *Nature* 2020; 578:306–310. Pubmed ID: 31969702
 3. Lin X, et al. ABBV-744, a first-in-class and highly selective inhibitor of the second bromodomain of BET family proteins, displays robust activities in preclinical models of acute myelogenous leukemia. *Cancer Res* 2018;78(13 Suppl):Abstract nr 800. Pubmed ID: DOI: 10.1158/1538-7445.AM2018-800

To reorder: <http://www.cellagentech.com/ABBV-744/>

For Technical Support: technical@cellagentech.com

Chemicals are sold for research use only, not for clinical or diagnostic use.